Jeremy is a biotechnology entrepreneur with extensive experience in the commercialisation of Australian technology, with a focus on business development and the management of early stage opportunities. Jeremy holds a PhD in physiology from the University of Canterbury (NZ) and is a Fellow of the Australian Institute of Company Directors (AICD).
He has over thirty years experience in the Australian healthcare market, initially by working with leading global multinational companies, including Merck & Co, Stryker, Becton Dickinson & Medtronic.
Sudha Rao – CSO
Sudha is Professor and Group Head for Gene Regulation and Translational Medicine at the QIMR Berghofer Medical Research Institute.
Sudha completed her PhD at Kings College London prior to moving to industry, where she gained valuable drug development experience. This included the development of phase 1 and 2 assets in asthma, rheumatoid arthritis and chronic obstructive pulmonary disease (COPD). Sudha was engaged by Aventis (now Sanofi) as a Senior Scientist for over 8 years before she was recruited to Australia in 2008 to work under Professor Frances Shannon and later Professor Chris Parish at the Australian National University. In 2010, Sudha moved to the University of Canberra where she was appointed Professor of Molecular & Cellular Biology until late 2019, before moving to Brisbane.
Professor Rao is internationally recognised for her domain expertise in epigenetics and cancer biology.
Brand has had a long and successful career in ICT both in Government and Private Industry. Brand is a successful entrepreneur, company director and investor. He founded TOWER Software which was acquired by HP in May of 2008. Brand has a degree in Computer Studies from the University of Canberra, has served as a Councillor of the University of Canberra and is now an Adjunct Professor at the University of Canberra.
Brand has served as a Director of NICTA, the Australian ICT Centre of Excellence, Taggle Systems, SNAPeWallet and MyTaggles Pty Ltds. Brand also served as Chairman of Canberra Business Council and a Councilor of the NSW Business Chamber. He has served as Chairman Australian Institute of Company Directors (AICD) Canberra Division and as a Director on the National Board of AICD. He was awarded the 2011 National Pearcey Medal, for a lifetime contribution to Australian ICT and in 2012 he was inducted as a Member into the Order of Australia.
Nick has an Honours Degree in Computing in Business from The University Huddersfield in the UK, an MBA from the University of South Australia and is a Graduate member of the Australian Institute of Company Directors.
He has a long track record of helping to build and grow early-stage companies, and has been a successful angel investor, business mentor, and CEO of a successful investment fund. Nick is a former Chair of Capital Angels, was a founding member of Sydney Angels. He currently sits on the Board of Entry29 and the GRIFFIN Accelerator.
Leigh is Professor and Deputy Vice-Chancellor for Research and Innovation at the University of Canberra. He has an international reputation for his research in geochemistry, especially on acid sulfate soils and carbon biosequestration.
Leigh holds a Bachelor of Science in Agriculture (Honors) and a Doctor of Philosophy from The University of Sydney. He has also published over 300 articles, books and chapters. Leigh was the Chair of the International Union of Soil Sciences’ Acid Sulfate Soil Working Group between 2002-2010 and then again between 2014-2018. Professor Sullivan has secured international patents arising from his research activities and is currently a Director of two R&D companies formed for the commercialisation of these discoveries.
There is a substantial unmet clinical need when it comes to fighting recurrent, metastatic breast cancer. This is the major cause of death in women with breast cancer. We aim to address that unmet need by the novel targeting of breast cancer stem cells, which are resistant to conventional systemic anticancer therapies and therefore contribute to the failure of these therapies in patients.
Professor Sudha Rao
Founder & Director at EpiAxis Therapeutics